Related Experiment Video
Updated: May 15, 2025

Analyzing the Parkinson's Disease Mouse Model Induced by Adeno-associated Viral Vectors Encoding Human α-Synuclein
Published on: July 29, 2022
Malondialdehyde Mediated Alpha-Synuclein Aggregation: A Plausible Etiology of Parkinson's Disease in Oxidative Stress
Harsh Thakkar1, Sayan Chatterjee2, Arvind Verma1
1Department of Pharmaceutical Analysis, National Institute of Pharmaceutical Education and Research - Ahmedabad (NIPER-A), Opposite Air force Station Palaj, Gandhinagar, Gujarat 382355, India.
Abstract:
Malondialdehyde (MDA), a major reactive byproduct of lipid peroxidation, has been implicated in numerous pathological conditions as a result of altering the structure and function of crucial proteins. One such protein is α-synuclein (α-Syn), which plays a vital role in the pathogenesis of Parkinson's disease (PD). This study investigates the hypothesis that MDA causes structural alterations in α-Syn, promoting its aggregation and exacerbating its toxicological effects. In vivo experiments were conducted where MDA and MDA-modified α-Syn were injected to the brain of mice. Behavioral assessments were performed to evaluate motor function changes, while immunohistochemistry was employed to examine the extent of α-Syn aggregation in brain tissues. An extraction protocol was also developed exquisitely, enabling quantification of modified α-Syn from brain tissue. Moreover, 15Nitrogen-labeled α-Syn was employed to establish an absolute quantification method on nLC-HRMS/MS. Our findings demonstrate that MDA-induced modifications in α-Syn alter its structural properties and also significantly enhance its aggregation propensity, potentially contributing to the neurodegenerative processes observed in PD. The developed model displayed a nonreversible decline in motor function, neurodegeneration, and aggregation of proteins in the brain mimicking the PD conditions. This research provides valuable insights into the molecular mechanisms of PD, emphasizing the role of MDA-modified proteins in the etiology of PD.
Insights
Malondialdehyde (MDA) modifies alpha-synuclein (α-Syn), promoting protein aggregation and motor deficits relevant to Parkinson's disease (PD). This study reveals MDA-induced α-Syn changes contribute to neurodegeneration in a PD mouse model.
Area of Science:
- Neuroscience
- Biochemistry
- Pathology
Background:
- Malondialdehyde (MDA), a lipid peroxidation byproduct, alters protein structure and function in disease.
- Alpha-synuclein (α-Syn) aggregation is central to Parkinson's disease (PD) pathogenesis.
- MDA's role in modifying α-Syn and its impact on PD are not fully understood.
Purpose of the Study:
- To investigate if MDA induces structural alterations in α-Syn, promoting aggregation and toxicity.
- To explore the potential contribution of MDA-modified α-Syn to Parkinson's disease mechanisms.
Main Methods:
- In vivo studies involving intracerebral injection of MDA and MDA-modified α-Syn in mice.
- Behavioral assessments for motor function, immunohistochemistry for α-Syn aggregation.
- Development of an extraction protocol and nLC-HRMS/MS with 15N-labeled α-Syn for absolute quantification.
Main Results:
- MDA-induced modifications significantly alter α-Syn structure and enhance its aggregation.
- The mouse model exhibited non-reversible motor function decline, neurodegeneration, and protein aggregation.
- Quantification methods successfully measured MDA-modified α-Syn in brain tissue.
Conclusions:
- MDA-modified α-Syn aggregation contributes to neurodegenerative processes mimicking PD.
- This study elucidates a molecular mechanism linking lipid peroxidation byproducts to PD etiology.
- Findings highlight the critical role of MDA-modified proteins in Parkinson's disease pathogenesis.
More Related Videos
06:07Author Spotlight: Establishing a New Fluorescence-Based Protocol for In Vivo Mitochondrial Morphology Analysis in Parkinson's Disease
Published on: June 23, 2023
10:03Studying Pre-formed Fibril Induced α-Synuclein Accumulation in Primary Embryonic Mouse Midbrain Dopamine Neurons
Published on: August 16, 2020
Related Concept Videos
Parkinson's Disease: Overview
Parkinson's Disease: Treatment
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Neural Regulation